Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

PTN

Palatin Technologies Inc

May 29 • 01:31PM ET

14.15

+0.15 1.07 %

Healthcare • Biotechnology • USA • Nano • NASD

Peers: BCTX CELU CLRB JSPR LGVN MRKR NXTC PLUR TPST VTGN

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.37	Insider Own	9.14%	Shs Outstand	1.78M	Perf Week	-1.94%
Market Cap	25.18M	Forward P/E	-	EPS next Y	-2.31	Insider Trans	-0.35%	Shs Float	1.62M	Perf Month	-30.19%
Enterprise Value	15.31M	PEG	-	EPS next Q	-1.20	Inst Own	55.58%	Short Float	9.65%	Perf Quarter	-32.30%
Income	-6.25M	P/S	1.95	EPS this Y	93.50%	Inst Trans	3.67%	Short Ratio	10.23	Perf Half Y	-23.92%
Sales	12.88M	P/B	2.37	EPS next Y	-10.69%	ROA	-73.72%	Short Interest	0.16M	Perf YTD	-8.00%
Book/sh	5.96	P/C	2.48	EPS next 5Y	53.79%	ROE	-297.24%	52W High	31.00 -54.35%	Perf Year	197.89%
Cash/sh	5.71	P/FCF	-	EPS past 3/5Y	44.66% 23.09%	ROIC	-58.46%	52W Low	4.51 214.10%	Perf 3Y	-88.40%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-3.40%	Volatility	4.32% 8.00%	Perf 5Y	-97.94%
Dividend TTM	-	EV/Sales	1.19	EPS Y/Y TTM	98.63%	Oper. Margin	-68.70%	ATR (14)	1.22	Perf 10Y	-97.88%
Dividend Ex-Date	-	Quick Ratio	5.04	Sales Y/Y TTM	3581.22%	Profit Margin	-48.50%	RSI (14)	33.99	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.04	EPS Q/Q	95.99%	SMA20	-14.99%	Beta	0.53	Target Price	53.50
Payout	-	Debt/Eq	0.03	Sales Q/Q	-	SMA50	-24.50%	Rel Volume	0.61	Prev Close	14.00
Employees	29	LT Debt/Eq	0.01	Earnings	May 13 BMO	SMA200	-7.58%	Avg Volume	15.28K	Price	14.15
IPO	Oct 28, 1993	Option/Short	No / Yes	EPS/Sales Surpr.	70.24% 207.04%	Trades		Volume	5,989	Change	1.07%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-12-25	Initiated	Laidlaw	Buy	$60
Dec-03-25	Initiated	Alliance Global Partners	Buy	$50

May-18-26 04:00PM	Palatin to Begin Trading on Nasdaq Stock Exchange (PR Newswire) +5.76% -6.36%
May-13-26 07:03PM	Palatin Technologies Inc (PTN) Q3 2026 Earnings Call Highlights: Strategic Advances Amidst ... (GuruFocus.com) -16.01% -9.82%
07:30AM	Palatin Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update (PR Newswire)
Feb-18-26 08:30AM	Palatin Technologies, Inc. Q2 2026 Earnings Call Summary (Moby) +10.01%
Feb-17-26 06:00PM	Palatin Technologies Inc (PTN) Q2 2026 Earnings Call Highlights: Strategic Advances Amid Rising ... (GuruFocus.com)
07:30AM	Loading…
07:30AM	Palatin Reports Second Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-13-25 07:30AM	Palatin Reports First Quarter Fiscal Year 2026 Financial Results and Provides Corporate Update (PR Newswire)
Nov-12-25 12:15PM	Palatin Technologies Announces Closing of Upsized $18.2 Million Public Offering with the Full Exercise of the Underwriters' Over-Allotment Option (PR Newswire) +29.43%

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Co-FounderDr. Carl Spana Ph.D.

MSTMr. Stephen T. Wills CPA

Vice President of Investor RelationsBurns McClellan

Chief Legal OfficerMr. Stephen A. Slusher Esq.

M.S.Mr. James E. Hattersley B.A.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
WILLS STEPHEN T	Executive VP and CFO/COO	Dec 24 '25	Sale	16.74	565	9,461	63,488	Dec 29 04:30 PM
WILLS STEPHEN T	Director	Dec 24 '25	Proposed Sale	16.74	565	9,461		Dec 29 10:42 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PTN

Palatin Technologies Inc

Upgrade your Finviz experience